Icotrokinra Trial for Ulcerative Colitis
Phase 3
882
about 6.3 years
12+
47 sites in AZ, CA, CO +17
What this study is about
Researchers are testing whether icotrokinra, a medication, can help people with moderately to severely active ulcerative colitis. The trial will last 2295 days and involve approximately 882 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Icotrokinra
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: DB Induction Study: Percentage of Adult Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), DB Induction Study: Percentage of Adult Participants with Fatigue Response at Week I-12, DB Induction Study: Percentage of Adult Participants with No Abdominal Pain at Week I-12, DB Maintenance Study: Percentage of Adult Participants with AEs and SAEs, DB Maintenance Study: Percentage of Adult Participants with Disease Clearance at Week M-40, DB Maintenance Study: Percentage of Adult Participants with Fatigue Response at Week M-40, DB Maintenance Study: Percentage of Adult Participants with No Abdominal Pain at Week M-40, OL Induction Phase: Percentage of Adolescent Participants with AEs and SAEs
Gastroenterology